UCSF U141 PHARMACOLOGY FINAL EXAM 2026/2027 | 150 EXAM PRACTICE
QUESTIONS AND CORRECT ANSWERS (VERIFIED ANSWERS) PLUS RATIONALES |
SCHOOL OF NURSING MEPN PREP | INSTANT DOWNLOAD
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–30)
1. A nurse is teaching a patient about a new prescription. The patient asks, "What happens to the drug
from the time I take it until it gets to my bloodstream?" The nurse's response is based on which phase
of pharmacokinetics?
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
Answer: B
Rationale: Absorption is the process by which a drug moves from its site of administration into the
bloodstream. Distribution is the transport of the drug to body tissues, metabolism is the breakdown of
the drug, and excretion is the removal of the drug from the body.
2. A patient with severe liver disease is prescribed a medication that is extensively metabolized by the
liver. The nurse anticipates that the patient may experience which effect?
A. A prolonged half-life and increased risk of toxicity
B. A decreased half-life and decreased therapeutic effect
C. No change in drug metabolism
D. Increased excretion of the drug by the kidneys
Answer: A
Rationale: The liver is the primary site of drug metabolism. In liver disease, the organ's ability to break
down drugs is impaired, leading to a prolonged drug half-life and a higher risk of drug accumulation and
toxicity.
3. A patient is administered a medication that binds to specific receptors on cell membranes, causing a
response that mimics the body's natural chemical. This drug is classified as a(n):
A. Antagonist
B. Agonist
,C. Enzyme inhibitor
D. Placebo
Answer: B
Rationale: An agonist binds to a receptor and produces a response. An antagonist binds to a receptor
but prevents a response.
4. A nurse is monitoring the serum drug level of a patient receiving an antibiotic with a narrow
therapeutic index. What is the primary reason for this monitoring?
A. To determine if the patient is taking the medication as prescribed
B. To ensure the drug is being absorbed properly
C. To maintain the drug level within a safe and effective range
D. To check for drug-drug interactions
Answer: C
Rationale: A narrow therapeutic index means there is a small margin between the effective dose and
the toxic dose. Monitoring peak and trough levels ensures the serum concentration stays within the
therapeutic window, maximizing efficacy and minimizing toxicity.
5. A 45-year-old patient is prescribed a lipophilic drug. Which pharmacokinetic parameter is most
significantly affected by a high percentage of total body fat?
A. Clearance
B. Volume of distribution (Vd)
C. Bioavailability
D. Renal elimination rate
Answer: B
Rationale: Lipophilic drugs distribute extensively into adipose tissue, significantly increasing the volume
of distribution (Vd). This can prolong the drug's half-life and duration of action.
6. Which of the following describes a drug that binds to a receptor and produces a submaximal
biological response even when occupying 100% of the receptors?
A. Competitive antagonist
B. Partial agonist
C. Full agonist
D. Inverse agonist
Answer: B
Rationale: A partial agonist binds to the receptor but produces a lower response than a full agonist,
,even at full receptor occupancy. A full agonist produces a maximal response, while an antagonist
produces no response.
7. In zero-order elimination kinetics, which of the following statements is true?
A. A constant fraction of drug is eliminated per unit time
B. Elimination rate is proportional to plasma drug concentration
C. A constant amount of drug is eliminated per unit time
D. The drug is eliminated exponentially
Answer: C
Rationale: In zero-order kinetics, the elimination rate is independent of plasma concentration, meaning
a constant amount of drug is eliminated per unit time. This occurs when the metabolic or excretory
pathways are saturated (e.g., with phenytoin or ethanol at high doses).
8. What is the first-pass effect?
A. Rapid renal clearance
B. Metabolism of an orally administered drug by the liver before it reaches systemic circulation
C. Enhanced absorption in the stomach
D. Protein binding in plasma
Answer: B
Rationale: Orally administered drugs absorbed from the GI tract pass through the portal circulation and
may be extensively metabolized by the liver before reaching systemic circulation, reducing their
bioavailability.
9. What is drug half-life?
A. Time to peak effect
B. Time required for the plasma concentration to decrease by 50%
C. Duration of receptor occupancy
D. Time to steady state only
Answer: B
Rationale: Half-life (t½) is the time required for the plasma concentration of a drug to decrease by 50%.
It determines the time to reach steady state (approximately 4–5 half-lives) and the dosing interval.
10. What is the definition of steady state?
A. The point at which drug absorption equals elimination, resulting in a constant plasma concentration
B. The peak plasma concentration
, C. The trough plasma concentration
D. The time to peak effect
Answer: A
Rationale: Steady state is reached when the rate of drug administration equals the rate of drug
elimination, resulting in a stable plasma concentration.
11. Which route of administration completely bypasses the absorption phase?
A. Oral
B. Intravenous
C. Intramuscular
D. Subcutaneous
Answer: B
Rationale: Intravenous administration places the drug directly into the bloodstream, eliminating the
absorption step. Bioavailability is 100% for IV drugs.
12. Which organ is the primary site of drug metabolism for most drugs?
A. Kidney
B. Liver
C. Lung
D. Spleen
Answer: B
Rationale: The liver is the principal organ of drug metabolism, primarily via the cytochrome P450
enzyme system.
13. Which organ is primarily responsible for the excretion of most drugs and their metabolites?
A. Liver
B. Kidneys
C. Skin
D. Intestine only
Answer: B
Rationale: Renal excretion is the major route for elimination of many drugs and their metabolites.
Renal function significantly affects drug half-life and dosing.
14. A medication with a narrow therapeutic index requires therapeutic drug monitoring. Which of the
following pairs represents drugs with a narrow therapeutic window?
QUESTIONS AND CORRECT ANSWERS (VERIFIED ANSWERS) PLUS RATIONALES |
SCHOOL OF NURSING MEPN PREP | INSTANT DOWNLOAD
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Questions 1–30)
1. A nurse is teaching a patient about a new prescription. The patient asks, "What happens to the drug
from the time I take it until it gets to my bloodstream?" The nurse's response is based on which phase
of pharmacokinetics?
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
Answer: B
Rationale: Absorption is the process by which a drug moves from its site of administration into the
bloodstream. Distribution is the transport of the drug to body tissues, metabolism is the breakdown of
the drug, and excretion is the removal of the drug from the body.
2. A patient with severe liver disease is prescribed a medication that is extensively metabolized by the
liver. The nurse anticipates that the patient may experience which effect?
A. A prolonged half-life and increased risk of toxicity
B. A decreased half-life and decreased therapeutic effect
C. No change in drug metabolism
D. Increased excretion of the drug by the kidneys
Answer: A
Rationale: The liver is the primary site of drug metabolism. In liver disease, the organ's ability to break
down drugs is impaired, leading to a prolonged drug half-life and a higher risk of drug accumulation and
toxicity.
3. A patient is administered a medication that binds to specific receptors on cell membranes, causing a
response that mimics the body's natural chemical. This drug is classified as a(n):
A. Antagonist
B. Agonist
,C. Enzyme inhibitor
D. Placebo
Answer: B
Rationale: An agonist binds to a receptor and produces a response. An antagonist binds to a receptor
but prevents a response.
4. A nurse is monitoring the serum drug level of a patient receiving an antibiotic with a narrow
therapeutic index. What is the primary reason for this monitoring?
A. To determine if the patient is taking the medication as prescribed
B. To ensure the drug is being absorbed properly
C. To maintain the drug level within a safe and effective range
D. To check for drug-drug interactions
Answer: C
Rationale: A narrow therapeutic index means there is a small margin between the effective dose and
the toxic dose. Monitoring peak and trough levels ensures the serum concentration stays within the
therapeutic window, maximizing efficacy and minimizing toxicity.
5. A 45-year-old patient is prescribed a lipophilic drug. Which pharmacokinetic parameter is most
significantly affected by a high percentage of total body fat?
A. Clearance
B. Volume of distribution (Vd)
C. Bioavailability
D. Renal elimination rate
Answer: B
Rationale: Lipophilic drugs distribute extensively into adipose tissue, significantly increasing the volume
of distribution (Vd). This can prolong the drug's half-life and duration of action.
6. Which of the following describes a drug that binds to a receptor and produces a submaximal
biological response even when occupying 100% of the receptors?
A. Competitive antagonist
B. Partial agonist
C. Full agonist
D. Inverse agonist
Answer: B
Rationale: A partial agonist binds to the receptor but produces a lower response than a full agonist,
,even at full receptor occupancy. A full agonist produces a maximal response, while an antagonist
produces no response.
7. In zero-order elimination kinetics, which of the following statements is true?
A. A constant fraction of drug is eliminated per unit time
B. Elimination rate is proportional to plasma drug concentration
C. A constant amount of drug is eliminated per unit time
D. The drug is eliminated exponentially
Answer: C
Rationale: In zero-order kinetics, the elimination rate is independent of plasma concentration, meaning
a constant amount of drug is eliminated per unit time. This occurs when the metabolic or excretory
pathways are saturated (e.g., with phenytoin or ethanol at high doses).
8. What is the first-pass effect?
A. Rapid renal clearance
B. Metabolism of an orally administered drug by the liver before it reaches systemic circulation
C. Enhanced absorption in the stomach
D. Protein binding in plasma
Answer: B
Rationale: Orally administered drugs absorbed from the GI tract pass through the portal circulation and
may be extensively metabolized by the liver before reaching systemic circulation, reducing their
bioavailability.
9. What is drug half-life?
A. Time to peak effect
B. Time required for the plasma concentration to decrease by 50%
C. Duration of receptor occupancy
D. Time to steady state only
Answer: B
Rationale: Half-life (t½) is the time required for the plasma concentration of a drug to decrease by 50%.
It determines the time to reach steady state (approximately 4–5 half-lives) and the dosing interval.
10. What is the definition of steady state?
A. The point at which drug absorption equals elimination, resulting in a constant plasma concentration
B. The peak plasma concentration
, C. The trough plasma concentration
D. The time to peak effect
Answer: A
Rationale: Steady state is reached when the rate of drug administration equals the rate of drug
elimination, resulting in a stable plasma concentration.
11. Which route of administration completely bypasses the absorption phase?
A. Oral
B. Intravenous
C. Intramuscular
D. Subcutaneous
Answer: B
Rationale: Intravenous administration places the drug directly into the bloodstream, eliminating the
absorption step. Bioavailability is 100% for IV drugs.
12. Which organ is the primary site of drug metabolism for most drugs?
A. Kidney
B. Liver
C. Lung
D. Spleen
Answer: B
Rationale: The liver is the principal organ of drug metabolism, primarily via the cytochrome P450
enzyme system.
13. Which organ is primarily responsible for the excretion of most drugs and their metabolites?
A. Liver
B. Kidneys
C. Skin
D. Intestine only
Answer: B
Rationale: Renal excretion is the major route for elimination of many drugs and their metabolites.
Renal function significantly affects drug half-life and dosing.
14. A medication with a narrow therapeutic index requires therapeutic drug monitoring. Which of the
following pairs represents drugs with a narrow therapeutic window?
